A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.
Also called NCT03922750
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 154 participants
- Sponsor
- Registry
-
NCT03922750 -
2018-003407-18
-
- Main results
- Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Germany, Italy
- Registry status
- Completed
Technical summary
Registry record NCT03922750. Randomized; no masking; primary purpose treatment. Start 2019-05-09 (actual); primary completion 2019-12-19 (actual). Results posted on 2021-01-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin icodec
- Intervention (Drug)
- Insulin glargine U100
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03922750- Content hash
f553657bb032570e706c2f9cfdfa07f354536b5c474eb7483b57c39786103121